Invention Grant
- Patent Title: Anti-CD277 antibodies
-
Application No.: US16896556Application Date: 2020-06-09
-
Publication No.: US11904004B2Publication Date: 2024-02-20
- Inventor: Daniel Olive , Marc Bonneville , Emmanuel Scotet , Christelle Harly , Yves Guillaume
- Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE D'AIX-MARSEILLE , INSTITUT JEAN PAOLI & IRENE CALMETTES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE DE NANTES
- Applicant Address: FR Paris
- Assignee: INSERM,UNIVERSITE D'AIX-MARSEILLE,INSTITUT JEAN PAOLI & IRENE CALMETTES,CNRS,UNIVERSITE DE NANTES
- Current Assignee: INSERM,UNIVERSITE D'AIX-MARSEILLE,INSTITUT JEAN PAOLI & IRENE CALMETTES,CNRS,UNIVERSITE DE NANTES
- Current Assignee Address: FR Paris; FR Marseilles; FR Marseill; FR Paris; FR Nantes
- Agency: WCF IP
- Priority: WO TIB2010003417 2010.12.15
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/28
Abstract:
Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of Vγ9/Vδ2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
Public/Granted literature
- US20200376104A1 ANTI-CD277 ANTIBODIES AND USES THEREOF Public/Granted day:2020-12-03
Information query
